Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronomic Temozolomide With Abexinostat for Recurrent High Grade Glioma
NCT05698524Phase 1Recruiting
- Sponsor
- University of Nebraska
- Start
- Jun 2023
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of abexinostat in high-grade glioma (HGG), sponsored by University of Nebraska. Primary endpoints: Adverse Events and Serious Adverse Events at 25 months and Recommended Dose Determination of PCI-24781/Abexinostat at 20 months. Started Jun 2023; status: recruiting.
02
Drugs
abexinostat
03
Conditions
high-grade glioma (HGG)
Beyond the preview
Go deeper on NCT05698524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05698524.